Psychological morbidity and stress but not social factors influence level of fear of cancer recurrence in young women with early breast cancer: results of a cross-sectional study

2013 ◽  
Vol 22 (12) ◽  
pp. 2797-2806 ◽  
Author(s):  
B. Thewes ◽  
M. L. Bell ◽  
P. Butow ◽  
J. Beith ◽  
F. Boyle ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Young Women ◽  
Social Factors ◽  
Cancer Recurrence ◽  
Cross Sectional Study ◽  
Fear Of Cancer Recurrence ◽  
Sectional Study ◽  
Cross Sectional ◽  
Fear Of Cancer

Fear of Cancer Recurrence after Curative Pancreatectomy: A Cross-sectional Study in Survivors of Pancreatic and Periampullary Tumors

2012 ◽  
Vol 19 (13) ◽  
pp. 4078-4084 ◽  
Author(s):  
Maria Q. B. Petzel ◽  
Nathan H. Parker ◽  
Alan D. Valentine ◽  
Sébastien Simard ◽  
Graciela M. Nogueras-Gonzalez ◽  
...  
Keyword(s):  
Cancer Recurrence ◽  
Cross Sectional Study ◽  
Fear Of Cancer Recurrence ◽  
Sectional Study ◽  
Cross Sectional ◽  
Periampullary Tumors ◽  
Fear Of Cancer

scholarly journals Fear of Cancer Recurrence Is Highly Prevalent and Linearly Associates With Anxiety and Depression in Chinese Breast Cancer Patients

2022 ◽  
Author(s):  
Zhensheng Li ◽  
Yue Li ◽  
Yunjiang Liu ◽  
Jun Zhang ◽  
Xiaohui Ji ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Recurrence ◽  
Depression Score ◽  
Fear Of Cancer Recurrence ◽  
Anxiety And Depression ◽  
Breast Cancer Patients ◽  
Distress Screening ◽  
Reference Analysis ◽  
Cross Sectional ◽  
Fear Of Cancer

Abstract Objective: To characterize the fear of cancer recurrence (FCR) and its relationship with anxiety and depression and quality of life (QoL) among Chinese breast cancer (BC) patients in China. Methods: Patients completed the questionnaires of QLQ-C30, QLQ-BR32 and HAD to assess FCR, QoL, anxiety and depression before radiotherapy. A cross-sectional analysis was performed. Chi-square and non-parametric tests and multivariate ordinal logistic regressions (mOLR) were utilized for reference analysis. Final covariates included age, BMI, TNM, surgery, chemotherapy, pain, and sleep disturbance. Results: From July 2015 to December 2016, 463 patients were prospectively enrolled. Their age mean (range) were 47 (19 - 89) years old. In total, 327 patients (70.6%) reported having FCR ‘a little bit’ (51.2%), ‘some’ (12.1%) and ‘very much’ (7.3%) in the past week. FCR severity ordered above (incl. ‘no’) was associated with anxiety score (median 1.5, 5.0, 7.0, 8.5 and level (‘abnormal’ rate 0%, 3.4%, 12.5%, 26.5%), depression score (median 2.0, 4.0, 6.0, 6.5) and level (‘abnormal’ rate 2.2%, 3.4%, 5.4%, 17.7%) (all p<0.001). mOLR showed that compared to ‘no’, three higher levels of FCR were associated with one level increase of anxiety with OR (p) as 1.983 (0.076), 4.291 (0.001), 8.282 (<0.001) and depression with OR (p) as 1.903 (0.062), 2.262 (0.065), 4.205 (0.004), respectively. FCR severity also was inversely associated with most QoL function scores (p<0.001). Conclusions: FCR was prevalent in Chinese BC patients and linearly associated with anxiety, depression and low QoL. It seems that a single-item question for FCR is a valid surrogate tool for distress screening in this population.

scholarly journals Switching of Hormone Therapies in Breast Cancer Women

2021 ◽  
Author(s):  
Luana Moreira de Medeiros ◽  
Rebeca Stahlschmidt ◽  
Amanda Canato Ferracini ◽  
Cinthia Madeira de Souza ◽  
Cassia Raquel Teatin Juliato ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Disease Progression ◽  
Cancer Recurrence ◽  
Cross Sectional Study ◽  
Cancer Center ◽  
Sectional Study ◽  
Single Institution ◽  
Cross Sectional ◽  
Hormone Therapies

Abstract Objective The objective of the present study was to analyze the reasons that led to hormone therapies (HTs) regimen changes in women with breast cancer. Methods This was a retrospective cross-sectional study from a single-institution Brazilian cancer center with patient records diagnosed with breast cancer between January 2012 and January 2017. Results From 1,555 women who were in treatment with HT, 213 (13.7%) women had HT switched, either tamoxifen to anastrozole or vice-versa. Most women included in the present study who switched HT were > 50 years old, postmenopausal, Caucasian, and had at least one comorbidity. From the group with therapy change, ‘disease progression’ was reason of change in 124 (58.2%) cases, and in 65 (30.5%) patients, ‘presence of side effects’ was the reason. From those women who suffered with side effects, 24 (36.9%) had comorbidities. Conclusion The present study demonstrated a low rate of HT switch of tamoxifen to anastrozole. Among the reasons for changing therapy, the most common was disease progression, which includes cancer recurrence, metastasis or increased tumor. Side effects were second; furthermore, age and comorbidities are risk factors for side effects.

Sign in / Sign up

Export Citation Format

Share Document